Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis

References

• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and patho physiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79–94
   PubMed Web of Science ®Google Scholar
• Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastro enterology 2004;126:1504–17
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association. Chronic intestinal disorders. In: The Burden of Gastrointestinal Diseases, Ch 4. Bethesda, MD: American Gastroenterological Association, 2001:30–42
   Google Scholar
• Loftus VE. Mortality in Crohn’s disease is increased. Evidence-based Gastroenterology 2002;3:102–3
   Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–63
   PubMed Web of Science ®Google Scholar
• Hjortswang H, Strom M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol 1998;93:2203–11
   Google Scholar
• Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306–10
   PubMed Web of Science ®Google Scholar
• Petrak F, Hardt J, Clement T, et al. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol 2001;36:375–82
   PubMed Web of Science ®Google Scholar
• Baert F, Vermeire S, Noman M, et al. Management of ulcerative colitis and Crohn’s disease. Acta Clinica Belgica 2004;59: 304–14
   PubMed Web of Science ®Google Scholar
• Carter MJ, Lobo AJ, Travis SPL, on behalf of the IBD Section of the British Society of Gastroenterology. Gut 2004;53(Suppl V):v1–16
   Google Scholar
• Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48–57; discussion 58
   Google Scholar
• Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582–92
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48–59
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171–84
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390–407
   PubMedGoogle Scholar
• Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991;324:84–8
   PubMed Web of Science ®Google Scholar
• Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990–6
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411(6837):599–603
   PubMed Web of Science ®Google Scholar
• Andersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001;344:808–14
   PubMed Web of Science ®Google Scholar
• Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastro enterology 2001;120:1093–9
   PubMed Web of Science ®Google Scholar
• Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619–22
   PubMed Web of Science ®Google Scholar
• Lindberg E, Tysk C, Andersson K, et al. Smoking and inflam matory bowel disease. A case control study. Gut 1988;29:352–7
   PubMed Web of Science ®Google Scholar
• Russel MG, Dorant E, Brummer RJ, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997;113:377–82
   Google Scholar
• Andersson RE, Olaison G, Tysk C, et al. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003;124:40–6
   PubMed Web of Science ®Google Scholar
• Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448–55
   PubMed Web of Science ®Google Scholar
• Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296–306
   PubMed Web of Science ®Google Scholar
• Kim SC et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005;128: 891–906
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immunol 1998;66:5224–31
   PubMed Web of Science ®Google Scholar
• Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immunol 2001;69:2277–85
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122: 44–54
   PubMed Web of Science ®Google Scholar
• Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003;21:105–28
   Google Scholar
• Kapp A. The role of cytokines in the psoriatic inflammation. J Dermatol Sci 1993;5133–42
   Google Scholar
• Edwards WE, Hallett MB. Seeing the wood for the tree: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997;18:320–4
   PubMedGoogle Scholar
• Grisham MB, Granger N. Mechanisms of neutophil-mediated tissue injury. In: MacDermott RP, Stenson WF, eds. Mechanisms of Neutophil-mediated Tissue Injury. New York: Elsevier, 1992:225–39
   Google Scholar
• Conner EM, Brand SJ, Davis JM, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Inflam Bowel Dis 1996;2:133–47
   PubMed Web of Science ®Google Scholar
• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182–205
   PubMed Web of Science ®Google Scholar
• Lim W-C, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004;4:104–17
   Google Scholar
• MacDermott RP. Progress in understanding the mechanisms of action of 5-amino salicylic acid. Am J Gastroenterol 2000;95:3343–5
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29
   PubMed Web of Science ®Google Scholar
• Bebb JR, Scott BB. September Review: How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20:143–9
   PubMed Web of Science ®Google Scholar
• Bebb SB, Scott BB. September Review: How effective are the usual treatments for Crohn’s disease? Aliment Pharmacol Ther 2004; 20:151–9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, et al. Combined data from two pivotal, randomized, placebo-controlled phase III studies show that SPD476, a novel mesalamine formation given once or twice daily is effective for the induction of remission of mild-to-moderate ulcerative colitis. Gastroenterology. 2006;130(Suppl 2):A-119. Abstract 813
   Google Scholar
• Herfarth H, Gross V, Andus T, et al. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn’s ileocolitis depending on disease activity and localization. Int J Colorectal Dis 2004;19: 147–52
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53. Epub 2005 Jun 21
   Google Scholar
• Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995;123:132–42
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76
   PubMed Web of Science ®Google Scholar
• Faber SM, Korelitz BI. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study. J Clin Gastroenterol 1993;17:213–8
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16: 69–77
   Google Scholar
• Thomsen OO, Cortot A, Jewell D, et al for the International Budesonide–Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn’s disease. N Engl J Med 1998;339:370–4
   Google Scholar
• Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23: 429–48
   PubMed Web of Science ®Google Scholar
• Schoon EJ, Bollani S, Mills PR, for the Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–21
   Google Scholar
• Egan LJ, Sandborn WJ. Advances in the treatment of Crohn’s disease. Gastroenterology 2004;126:1574–81
   PubMed Web of Science ®Google Scholar
• Sparrow M, Hande SA, Friedman S, et al. Optimization of 6-thioguanine production by allopurinol in IBD patients not responding to azathioprine/6-mercaptopurine leads to improved disease activity, reduced corticosteroid requirements, and normalization of liver enzymes. Gastroenterology. 2006;130(Suppl 2):A-142. Abstract 922
   Google Scholar
• Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347(8996):215–9
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641–9
   PubMed Web of Science ®Google Scholar
• Seksik P, Cosnes J, Nion-Larmurier I, et al. Incidence of infections in IBD patients treated with azathioprine. Gastroenterology. 2006;130(Suppl 2):A-72. Abstract 493
   Google Scholar
• Remicade [package insert]. Malverne, Pa: Centocor, Inc.; 2006
   Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337: 1029–35
   Google Scholar
• Kusugami K, Ina K, Ando T, et al. Immunomodulatory therapy for inflammatory bowel disease. J Gastroenterol 2004;39:1129–37
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9
   Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912–20
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ. Review article: efficacy of infliximab in Crohn’s disease – induction and maintenance of remission. Aliment Pharmacol Ther 1999;13(Suppl 4):9–15
   PubMedGoogle Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601–18
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72: 250–6
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab and other Crohn’s disease therapies – TREAT™ registry data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006;130(Suppl 2):A-71. Abstract 490
   Google Scholar
• Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther Apher Dial 2003;7:44–7
   PubMed Web of Science ®Google Scholar
• Ohara M, Saniabadi AR, Kokuma S, et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989–94
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171–84
   PubMed Web of Science ®Google Scholar
• Ohara M, Saniabadi AR, Kokuma S, et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989–94
   PubMed Web of Science ®Google Scholar
• Hiraishi K, Takeda Y, Shiobara N, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003;7:334–40
   PubMed Web of Science ®Google Scholar
• Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334–41
   PubMed Web of Science ®Google Scholar
• Hanai H, Takeuchi K, Iida T, et al. Release of IL-10, IL-1 receptor antagonist, soluble TNF-A receptors I and II during adsorptive granulocyte and monocyte/macrophage reduction therapy of patients with active ulcerative colitis. Program and abstracts of Digestive Disease Week; May 15–20, 2004; New Orleans, La. Abstract W1093
   Google Scholar
• Hanai H, Iida T, Yamada M, et al. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006;12:3393–9
   PubMed Web of Science ®Google Scholar
• Sakimura K, Omori T, Iwashita E, et al. Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:1525–31
   PubMed Web of Science ®Google Scholar
• Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435–41
   PubMed Web of Science ®Google Scholar
• Koike Y, Inoue N, Naganuma M, et al. The formation of leuko cyte-platelets complex in patients with ulcerative colitis: a novel marker for the disease activity and response to granulo cytapheresis. Program and abstracts of Digestive Disease Week; May 15–20, 2004; New Orleans, La. Abstract W1109
   Google Scholar
• Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28–35
   PubMed Web of Science ®Google Scholar
• Hanai H, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte/macrophage apheresis versus prednisolone in patients with corticosteroid-dependent ulcerative colitis. Digestion 2004;70:36–44
   PubMed Web of Science ®Google Scholar
• Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251–7
   PubMed Web of Science ®Google Scholar
• Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronic ally active steroid refractory ulcerative colitis. World J Gastro enterol 2005;11:7001–6
   Google Scholar
• Sawada K, Shimoyama T, Hiwatashi N, et al. A multicenter randomized controlled study of safety and efficacy of adsorptive granulocyte and monocyte apheresis in patients with active ulcerative colitis. Program and abstracts of Digestive Disease Week; May 15–20, 2004; New Orleans, La. Abstract T1288
   Google Scholar
• Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001;16:1–9
   PubMed Web of Science ®Google Scholar
• Domenech E, Hinojosa J, Esteve-Comas M, et al, for the Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Granulocytapheresis in steroid-dependent inflam matory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20: 1347–52
   Google Scholar
• Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565–71
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Sato T, Iwagami Y, et al. Intermittent therapy with granulocyte and monocyte apheresis maintains remission in ulcerative colitis. Gastroenterology 2004;126:A466–7
   Google Scholar
• Sands BE, Sandborn WJ, Wolf DC, et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482–9
   PubMed Web of Science ®Google Scholar
• Kanke K, Nakano M, Hiraishi H, et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:811–7
   PubMedGoogle Scholar
• Giampaolo B, Giuseppe P, Michele B, et al. Treatment of active steroid-refractory inflammatory bowel diseases with granulo cytapheresis: Our experience with a prospective study. World J Gastroenterol 2006;12:2201–4
   PubMed Web of Science ®Google Scholar
• Tanaka T, Okanobu H, Saniabadi AR, et al. Efficacy of Adacolumn selective leukocytapheresis in patients with steroid naive and steroid dependent with moderate to severe ulcerative colitis. Gastroenterology 2006;130(Suppl 2):A-483. Abstract S1390
   Google Scholar
• Suzuki Y, Aoki H, Nakamura K, et al. Adacolumn selective leukocytapheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma interleukin-8 and the expression of toll like receptors on granulocytes. Gastroenterology 2006;130(Suppl 2):A-657. Abstract W1204
   Google Scholar
• Yeh JH, Chiu HC. Plasmapheresis-related hypotension. Artif Organs 2000;24:705–9
   PubMed Web of Science ®Google Scholar
• Norda R, Stegamyr BG, for the Swedish Apheresis Group. Thera peutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003;29:159–66
   Google Scholar
• Stegmayr B, Ptak J, Wikstrom B, et al. World apheresis registry: report of 2004 data. Ther Apher Dial 2005;9:A38. Abstract
   Google Scholar